Pluristem Joins Both the TA-75 and TA-100 Indexes on the Tel Aviv Stock Exchange

Pluristem Joins Both the TA-75 and TA-100 Indexes on the Tel Aviv Stock

HAIFA, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today it has been informed by the Tel Aviv Stock Exchange
(TASE) that its shares are now listed in both the Tel-Aviv-75 (TA-75) and the
Tel Aviv-100 (TA-100) Index effective December 16, 2012. The TA-100 index
tracks the top 100 companies listed on TASE weighted by market capitalization.

"We are proud to be included in this important Tel Aviv Stock Exchange index
and to become one of the 100 most highly capitalized companies on the
exchange," said Zami Aberman, Chairman and CEO of Pluristem. "Our inclusion in
this index positions us as one of the top Israeli-based biotechnology
companies and is another step in our evolution as a leading global publicly
traded biotech company. Additionally, this designation places us on the radar
screen of many Israeli fund managers, in particular those who follow and track
this index."

About TA-75

The TA-75 Index is one of the TASE's leading indices, published from 1999. The
index tracks the 75 shares with the highest market capitalization not included
in the TA-25 index.

About TA-100

The TA-100 Index is one of the TASE's leading indices, published from 1992.
The index consists of the 100 shares with the highest market capitalization
that are included in the TA-25 and TA-75 indices.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the effects
and implications of our inclusion in the Tel-Aviv-75 (TA-75) and the Tel
Aviv-100 (TA-100) Indexes, we are using forward-looking statements. These
forward-looking statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved
by regulatory agencies, our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community; we
may be unable to retain or attract key employees whose knowledge is essential
to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than
we anticipate; results in the laboratory may not translate to equally good
results in real surgical settings; results of preclinical studies may not
correlate with the results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.